News
The companies' new effort would bypass traditional middlemen to cut the drug's monthly cost from a list price of around $606 ...
Bristol Myers and Pfizer said on Thursday they will start selling their blockbuster blood thinner, Eliquis, directly to ...
The program is the latest example of pharmaceutical companies bypassing traditional drug distribution channels for people who ...
The joint venture is launching a direct-to-consumer service of Eliquis after discussions with the Trump administration.
Drugmakers will offer Eliquis at a 43% discount to uninsured U.S. patients, bypassing insurers and PBMs New $346 monthly ...
Pharmaceutical giants introduce an insurance-free pathway for top anticoagulant Eliquis, following similar direct-to-patient models from Eli Lilly and Novo Nordisk.
Taking a page from Eli Lilly and Novo Nordisk, who have launched online programs to sell their diabetes and obesity drugs ...
Morgan Stanley identified Bristol-Myers Squibb (NYSE:BMY) as a catalyst-driven idea ahead of a key data readout for Cobenfy in Alzheimer’s Disease Psychosis (ADP), expected in late third or early ...
Bristol Myers Squibb Co. closed 26.69% short of its 52-week high of $63.33, which the company achieved on March 11th.
Bristol Myers Squibb Co. closed 25.25% below its 52-week high of $63.33, which the company reached on March 11th.
Bristol Myers Squibb has opened its radiopharmaceutical manufacturing facility in Indianapolis, which played a major role in ...
BofA cuts Bristol Myers' 2025 EPS and sales estimates slightly and flags medium-term pressure from generics, while ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results